Literature DB >> 26394528

Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells.

Paolina Pantcheva1, Stephanny Reyes1, Jaclyn Hoover1, Sussannah Kaelber1, Cesar V Borlongan.   

Abstract

Parkinson's disease (PD) treatment-based research has focused on developing therapies for the management of motor symptoms. Non-motor symptoms do not respond to treatments targeting motor deficits, thus necessitating an urgent need to develop new modalities that cater to both motor and non-motor deficits. Stem cell transplantation is potentially therapeutic for PD, but the disease non-motor symptoms have been primarily neglected in such cell therapy regimens. Many types of stem cells are currently available for transplantation therapy, including adult tissue (e.g., bone marrow, placenta)-derived mesenchymal stem cells. The fact that mesenchymal stem cells can replace and rescue degenerated dopaminergic and non-dopaminergic cells suggests their potential for the treatment of motor as well as non-motor symptoms of PD, which is discussed in this article.

Entities:  

Keywords:  Parkinson’s disease; mesenchymal stem cells; motor symptoms; non-motor symptoms; stem cell therapy

Mesh:

Year:  2015        PMID: 26394528      PMCID: PMC4828972          DOI: 10.1586/14737175.2015.1091727

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  84 in total

1.  Isolation of multipotent mesenchymal stem cells from umbilical cord blood.

Authors:  Oscar K Lee; Tom K Kuo; Wei-Ming Chen; Kuan-Der Lee; Shie-Liang Hsieh; Tain-Hsiung Chen
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

2.  Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease.

Authors:  J H Kordower; T B Freeman; E Y Chen; E J Mufson; P R Sanberg; R A Hauser; B Snow; C W Olanow
Journal:  Mov Disord       Date:  1998-05       Impact factor: 10.338

3.  Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants.

Authors:  Marios Politis; Kit Wu; Clare Loane; Niall P Quinn; David J Brooks; Stig Rehncrona; Anders Bjorklund; Olle Lindvall; Paola Piccini
Journal:  Sci Transl Med       Date:  2010-06-30       Impact factor: 17.956

4.  Stem and progenitor cell-based therapy of the human central nervous system.

Authors:  Steve Goldman
Journal:  Nat Biotechnol       Date:  2005-07       Impact factor: 54.908

5.  Dopaminergic differentiation of neural progenitors derived from placental mesenchymal stem cells in the brains of Parkinson's disease model rats and alleviation of asymmetric rotational behavior.

Authors:  Saeyoung Park; Eungpil Kim; Seong-Eun Koh; Sungho Maeng; Won-Don Lee; Jinho Lim; Insop Shim; Young-Jay Lee
Journal:  Brain Res       Date:  2012-05-24       Impact factor: 3.252

6.  Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease.

Authors:  Neelam K Venkataramana; Satish K V Kumar; Sudheer Balaraju; Radhika Chemmangattu Radhakrishnan; Abhilash Bansal; Ashish Dixit; Deepthi K Rao; Madhulita Das; Majahar Jan; Pawan Kumar Gupta; Satish M Totey
Journal:  Transl Res       Date:  2009-08-06       Impact factor: 7.012

Review 7.  Stem cell-derived dopamine neurons for brain repair in Parkinson's disease.

Authors:  Rosemary A Fricker-Gates; Monte A Gates
Journal:  Regen Med       Date:  2010-03       Impact factor: 3.806

8.  Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells.

Authors:  Cha-Gyun Jung; Hideki Hida; Kensuke Nakahira; Kazuhiro Ikenaka; Hye-Jung Kim; Hitoo Nishino
Journal:  FASEB J       Date:  2004-06-04       Impact factor: 5.191

9.  Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells.

Authors:  D Eugene Redmond; Kimberly B Bjugstad; Yang D Teng; Vaclav Ourednik; Jitka Ourednik; Dustin R Wakeman; Xuejun H Parsons; Rodolfo Gonzalez; Barbara C Blanchard; Seung U Kim; Zezong Gu; Stuart A Lipton; Eleni A Markakis; Robert H Roth; John D Elsworth; John R Sladek; Richard L Sidman; Evan Y Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-22       Impact factor: 11.205

Review 10.  Local control of striatal dopamine release.

Authors:  Roger Cachope; Joseph F Cheer
Journal:  Front Behav Neurosci       Date:  2014-05-23       Impact factor: 3.558

View more
  10 in total

1.  Fatty acid chemical mediator provides insights into the pathology and treatment of Parkinson's disease.

Authors:  Cesar V Borlongan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-30       Impact factor: 11.205

2.  A Gutsy Move for Cell-Based Regenerative Medicine in Parkinson's Disease: Targeting the Gut Microbiome to Sequester Inflammation and Neurotoxicity.

Authors:  Jea-Young Lee; Julian P Tuazon; Sydney Corey; Brooke Bonsack; Sandra Acosta; Jared Ehrhart; Paul R Sanberg; Cesario V Borlongan
Journal:  Stem Cell Rev Rep       Date:  2019-10       Impact factor: 6.692

Review 3.  Guts Imbalance Imbalances the Brain: A Review of Gut Microbiota Association With Neurological and Psychiatric Disorders.

Authors:  Laura Mitrea; Silvia-Amalia Nemeş; Katalin Szabo; Bernadette-Emőke Teleky; Dan-Cristian Vodnar
Journal:  Front Med (Lausanne)       Date:  2022-03-31

4.  Antagonization of the Nogo-Receptor 1 Enhances Dopaminergic Fiber Outgrowth of Transplants in a Rat Model of Parkinson's Disease.

Authors:  Stefanie Seiler; Stefano Di Santo; Lukas Andereggen; Hans R Widmer
Journal:  Front Cell Neurosci       Date:  2017-05-26       Impact factor: 5.505

Review 5.  Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson's Disease?

Authors:  Helena Vilaça-Faria; António J Salgado; Fábio G Teixeira
Journal:  Cells       Date:  2019-02-02       Impact factor: 6.600

6.  Gutting the brain of inflammation: A key role of gut microbiome in human umbilical cord blood plasma therapy in Parkinson's disease model.

Authors:  Jea-Young Lee; Julian P Tuazon; Jared Ehrhart; Paul R Sanberg; Cesario V Borlongan
Journal:  J Cell Mol Med       Date:  2019-05-31       Impact factor: 5.310

7.  Non-Motor Symptoms after One Week of High Cadence Cycling in Parkinson's Disease.

Authors:  Sara A Harper; Bryan T Dowdell; Jin Hyun Kim; Brandon S Pollock; Angela L Ridgel
Journal:  Int J Environ Res Public Health       Date:  2019-06-14       Impact factor: 3.390

Review 8.  Enriched Environment and Exercise Enhance Stem Cell Therapy for Stroke, Parkinson's Disease, and Huntington's Disease.

Authors:  Reed Berlet; Dorothy Anne Galang Cabantan; Daniel Gonzales-Portillo; Cesar V Borlongan
Journal:  Front Cell Dev Biol       Date:  2022-03-03

Review 9.  Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease.

Authors:  Dominika Fričová; Jennifer A Korchak; Abba C Zubair
Journal:  NPJ Regen Med       Date:  2020-11-03

10.  Reelin Alleviates Mesenchymal Stem Cell Senescence and Reduces Pathological α-Synuclein Expression in an In Vitro Model of Parkinson's Disease.

Authors:  Eunju Cho; Joonsang Park; Kyungri Kim; Min-Gi Kim; Sung-Rae Cho
Journal:  Genes (Basel)       Date:  2021-07-13       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.